Different strategies for B7-H3 targeting in cancer treatment are illustrated in Figure 1, Table 2, Table 3 and Table 4 present ongoing clinical trials, while Table 5 presents completed trials involving B7-H3 blockade, respectively. Here, CD276 is linked to cancer.